HealthRecon Connect LLC’s Post

⭐ 5 Best Practices to Reduce the Pain (and Risk) of 340B ⭐ The federal 340B Drug Pricing Program offers plenty of financial and patient care benefits to healthcare providers, but it can also cause headaches for organizations that don’t have the internal expertise or resources to navigate it. 😣 Our latest article is outlining the five best practices to make 340B easier for you. The first: Understand your organization's risk, including how activity flows through the program. So how do you go about doing that? And what are the four other best practices? Dive into our article to find out: https://ow.ly/rW7y50SQhg2 #Healthcare #PatientCare #340B

📊 Post-Election Healthcare Policy Briefing: What's Next for 340B? With the election behind us, the healthcare industry is buzzing with questions about the future of the 340B Drug Pricing Program. Join us for a timely webinar where we’ll break down the post-election landscape and explore what’s on the horizon for 340B. Join Anthony Velasquez and Justin Rolling, CPA as they analyze the shifting landscape of healthcare policy and drug pricing reform in our upcoming webinar. Get actionable insights on: - Election impact on 340B legislation - State-level developments including CA Prop 34 - Critical HHS leadership changes - SUSTAIN 340B Act implications - PBM accountability measures Register now to stay ahead of policy changes that may impact your organization: https://hubs.la/Q02Y_Fmv0 #HealthcarePolicy #340B #PharmaLeadership #HealthcareBusiness

In today's healthcare landscape, CMS Star Ratings directly impact the financial success of Medicare Advantage and Part D prescription drug plans (MAPD) by influencing which plans members select. #Health plans can use AI-first strategies and incorporate #GenAI tools to identify and engage members, and deliver personalized experiences that address each individual’s unique needs. Learn how you can get started: https://lnkd.in/gmED_jGz #HealthcareEquity #AIInnovation #CMSRatings #DataDrivenHealthcare Deepan Vashi Priyanka Grover Nikita Agrawal

⭐ 5 Best Practices to Reduce the Pain (and Risk) of 340B ⭐ The federal 340B Drug Pricing Program offers plenty of financial and patient care benefits to healthcare providers, but it can also cause headaches for organizations that don’t have the internal expertise or resources to navigate it. 😣 Our latest article is outlining the five best practices to make 340B easier for you. The first: Understand your organization's risk, including how activity flows through the program. So how do you go about doing that? And what are the four other best practices? Dive into our article to find out: https://ow.ly/91Rv50SX10k #Healthcare #PatientCare #340B

Preparing for Changes to Group Medicare in 2025 Understanding the full impacts of the Inflation Reduction Act (IRA) & CMS program changes is a challenge. Our white paper summarizes updates to Medicare Advantage and Part D prescription drug coverage with actionable information and strategies for adapting to these shifts in retiree healthcare. Download now: https://bit.ly/3Tc76mB

🚨 The Fifth Circuit has revived a legal challenge to the federal Drug Price Negotiation Program, a potential game-changer for healthcare providers. This decision could impact pricing dynamics and reshape how providers manage drug costs. Stay informed on the evolving landscape and its implications for the healthcare industry. #HealthcareProviders #DrugPricing #LegalUpdate #HealthcarePolicy

Preparing for Changes to Group Medicare in 2025 Understanding the full impacts of the Inflation Reduction Act (IRA) & CMS program changes is a challenge. Our white paper summarizes updates to Medicare Advantage and Part D prescription drug coverage with actionable information and strategies for adapting to these shifts in retiree healthcare. Download now: https://bit.ly/3Mw1hMM

⭐ 5 Best Practices to Reduce the Pain (and Risk) of 340B ⭐ The federal 340B Drug Pricing Program offers plenty of financial and patient care benefits to healthcare providers, but it can also cause headaches for organizations that don’t have the internal expertise or resources to navigate it. 😣 Our latest article is outlining the five best practices to make 340B easier for you. The first: Understand your organization's risk, including how activity flows through the program. So how do you go about doing that? And what are the four other best practices? Dive into our article to find out: https://ow.ly/ggQl50SRe4B #Healthcare #PatientCare #340B

⭐ 5 Best Practices to Reduce the Pain (and Risk) of 340B ⭐ The federal 340B Drug Pricing Program offers plenty of financial and patient care benefits to healthcare providers, but it can also cause headaches for organizations that don’t have the internal expertise or resources to navigate it. 😣 Our latest article is outlining the five best practices to make 340B easier for you. The first: Understand your organization's risk, including how activity flows through the program. So how do you go about doing that? And what are the four other best practices? Dive into our article to find out: https://ow.ly/nXUo50SWmcU #Healthcare #PatientCare #340B

Employers, a friendly reminder: The deadline to submit your RxDC report to CMS is June 1, 2024, for the 2023 data period. This crucial report details your group health plans' prescription drug and healthcare expenses. Good news! Most of our carriers are proactively handling this submission for their clients, and they may reach out to you for the necessary data. Please coordinate with your issuers, TPAs, or PBMs to ensure this process is seamless. For those with self-insured plans, remember you bear the ultimate responsibility for compliance. Start preparing now to ensure a hassle-free submission. #HealthcareReporting #RxDCReport #CMS #EmployeeBenefits